Substance / Medication

Pentamidine isethionate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Trypanosomiasis

Protozoal intestinal disease

Protozoosis

Visceral leishmaniasis

Pneumocystosis pneumonia

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

3 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis

NCT00604955Phase 4Completed2000 enrolled

Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children

NCT01032187Phase 4Completed101 enrolled

Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh

NCT03311607Phase 4Completed280 enrolled

View all 3 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Efficacy and safety of pentamidine isethionate for tegumentary and visceral human leishmaniasis: a systematic review.

Piccica Matteo, Lagi Filippo, Bartoloni Alessandro et al. · J Travel Med · 2021

PMID: 33890115Meta-Analysis

Randomized single-blinded non-inferiority trial of 7 mg/kg pentamidine isethionate versus 4 mg/kg pentamidine isethionate for cutaneous leishmaniaisis in Suriname.

Hu Ricardo V P F, Straetemans Masja, Kent Alida D et al. · PLoS Negl Trop Dis · 2015

PMID: 25793773RCTFull text (PMC)

Monitoring the response of patients with cutaneous leishmaniasis to treatment with pentamidine isethionate by quantitative real-time PCR, and identification of Leishmania parasites not responding to therapy.

Mans D R A, Kent A D, Hu R V et al. · Clin Exp Dermatol · 2016

PMID: 26648589Observational

Comparison between one and two injections of pentamidine isethionate, at 7 mg/kg in each injection, in the treatment of cutaneous leishmaniasis in French Guiana.

Roussel M, Nacher M, Frémont G et al. · Ann Trop Med Parasitol · 2006

PMID: 16762111Observational

Case Report: Combination Therapy with Liposomal Amphotericin B, N-Methyl Meglumine Antimoniate, and Pentamidine Isethionate for Disseminated Visceral Leishmaniasis in a Splenectomized Adult Patient.

Vechi Hareton Teixeira, Sousa Ana Solange Vasconcelos de, Cunha Mirella Alves da et al. · Am J Trop Med Hyg · 2020

PMID: 31872796Case ReportFull text (PMC)

Good response to pentamidine isethionate in a case of Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis that was difficult to treat: Case Report.

Ferreira Terceiro Benivaldo Ramos, Torraca Tania Salgado de Souza, Braga Frederico Pereira Bom et al. · Rev Soc Bras Med Trop · 2019

PMID: 30652793Case Report

Efficacy of short-course intramuscular pentamidine isethionate treatment on Old World localized cutaneous leishmaniasis in 2 patients.

Jauréguiberry Stephane, Graby Gentiane, Caumes Eric · Clin Infect Dis · 2006

PMID: 16705598Case Report

Pentamidine isethionate as treatment and secondary prophylaxis for disseminated cutaneous leishmaniasis during HIV infection: case report.

Calza L, Marinacci G, Manfredi R et al. · J Chemother · 2001

PMID: 11806628Case Report

The In Vitro Effects of Pentamidine Isethionate on Coagulation and Fibrinolysis.

Al-Horani Rami A, Clemons Daytriona, Mottamal Madhusoodanan · Molecules · 2019

PMID: 31174390OtherFull text (PMC)

An open label randomized clinical trial comparing the safety and effectiveness of one, two or three weekly pentamidine isethionate doses (seven milligrams per kilogram) in the treatment of cutaneous leishmaniasis in the Amazon Region.

Gadelha Ellen Priscilla Nunes, Ramasawmy Rajendranath, da Costa Oliveira Bruna et al. · PLoS Negl Trop Dis · 2018

PMID: 30379814TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Pentamidine isethionate (substance)
SNOMED CT: 16826009
UMLS CUI: C0030864

Clinical Data

This intervention maps to 5 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.